Thrombus Formation and Propagation in the Onset of Cardiovascular Events

Yujiro Asada¹, Atsushi Yamashita¹, Yuichiro Sato² and Kinta Hatakeyama³

¹Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
²Department of Diagnostic Pathology, University of Miyazaki Hospital, University of Miyazaki, Miyazaki, Japan
³Department of Diagnostic Pathology, Nara Medical University, Nara, Japan

Ischemic cardiovascular disease is a major cause of morbidity and mortality worldwide and thrombus formation on disrupted atherosclerotic plaques is considered to trigger its onset. Although the activation of platelets and coagulation pathways has been investigated intensively, the mechanisms of thrombus formation on disrupted plaques have not been understood in detail. Platelets are thought to play a central role in the formation of arterial thrombus because of rapid flow conditions; however, thrombus that develops on disrupted plaques consistently includes large amounts of fibrin in addition to aggregated platelets. While, thrombus does not always become large enough to completely occlude the vascular lumen, indicating that the propagation of thrombus is also critical for the onset of cardiovascular events. Various factors, such as vascular wall thrombogenicity, altered blood flow and imbalanced blood hemostasis, modulate thrombus formation and propagation on disrupted plaques. Pathological findings derived from humans and experimental animal models of atherothrombosis have identified important factors that affect thrombus formation and propagation, namely platelets, extrinsic and intrinsic coagulation factors, proinflammatory factors, plaque hypoxia and blood flow alteration. These findings might provide insight into the mechanisms of thrombus formation and propagation on disrupted plaques that lead to the onset of cardiovascular events.

Key words: Atherothrombosis, Platelet, Tissue factor, Blood flow, Factor XI

Introduction

Thrombus formation on disrupted atherosclerotic plaques is generally considered as being a trigger for atherothrombosis, namely the onset of cardiovascular events. Since thrombus does not always become large enough to completely occlude vessels with subsequent acute symptomatic events, thrombus propagation is also critical to the onset of clinical events. Thrombus formation is modulated by factors, including the thrombogenicity of plaques and blood, local hemorheology and proinflammatory factors. Although the activation of platelets and coagulation pathways has been intensively investigated, the mechanisms involved in thrombogenesis or thrombus propagation at plaque disruption sites remain obscure.

Many studies of experimental animals have determined the molecular mechanisms of thrombus formation. However, the mechanisms of thrombus formation and propagation in atherosclerotic vessels remain vague because thrombi are induced in the “normal” arteries of many experimental animal models via chemical or physical damage. Since atherothrombosis develops on disrupted atherosclerotic plaque, vascular wall components and associated blood flow alterations are essential factors for thrombogenesis.

This article examines the mechanisms of thrombus formation and propagation on disrupted atherosclerotic plaques from pathological aspects, including recently identified factors.

Pathology of Plaque Disruption

The underlying mechanisms of the onset of cardiovascular events comprise plaque rupture and plaque erosion (Fig. 1).
Plaque rupture is the most common cause of acute coronary syndrome (ACS), and it is induced by fibrous cap disruption that allows blood to contact a highly thrombogenic necrotized core, resulting in thrombus formation. It is likely rupture occurs in plaques with a large necrotic core, fibrous caps that are usually < 65 µm thick, and the massive infiltration of macrophages, T lymphocytes and occasional smooth muscle cells (SMC)²⁻³. Accumulating evidence supports the notion that inflammation plays a key role in the pathogenesis of plaque rupture. Macrophages mainly with the M1 phenotype⁴ overexpress proteolytic enzymes in plaques. In addition, activated T lymphocytes and macrophages secrete interferon γ, which inhibits collagen synthesis and induces SMC apoptosis⁵. These findings show that inflammatory pathways significantly participate in plaque destabilization.

Plaque erosion is responsible for 22%–44% of ACS⁶, which is characterized by an absence of endothelium or intimal injury without reaching lipid core. The morphological characteristics include an abundance of SMC and proteoglycan matrix, especially versican and hyaluronan, whereas the necrotic core is small or absent and macrophages and T cells are scant²⁻³. Patients with plaque erosion are younger, and unlike those with plaque rupture, males do not predominate⁶. Mechanisms that might contribute to erosion include endothelial dysfunction, hemodynamic forces, hyper-vasoconstriction and sub-endothelial matrix modification; however, details remain unclear⁶. A contribution of Toll-like receptor 2 and neutrophil activation has recently been reported⁷.

**Pathology of Thrombus on Disrupted Plaques**

Arterial thrombi are thought to mainly comprise aggregated platelets because of rapid flow conditions. However, thrombi that develop on disrupted plaques consist of not only aggregated platelets, but also large amounts of fibrin in addition to other types of blood cells (Fig. 1)⁸⁻¹⁰. In addition, the proportions of fibrin and platelets differs between coronary thrombi on ruptured and eroded plaques, which are fibrin- and rather...
Platelet Activation on Plaques

Platelet activation at the sites of disrupted plaques is an initial step in the formation of thrombus. Activated platelets release adenosine diphosphate (ADP), serotonin and thromboxane A2, which promote platelet activation further. This self-amplifying process results in thrombus propagation. In addition, released adenosine triphosphate (ATP) from erythrocytes and leukocytes can also activate platelets. Because ADP and ATP play key roles in platelet aggregation, their metabolisms in the bloodstream are important for the regulation of platelet activation and recruitment.

1) Ecto-Nucleoside Triphosphate Diphosphohydrolase

Ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase, CD39) is a membrane-bound enzyme that rapidly hydrolyzes both ADP and ATP to AMP and thereby inhibits platelet activation and thrombus formation. Endothelial E-NTPDase expression is down-regulated under conditions of inflammation and disrupted blood flow. Hatakeyama et al. showed that E-NTPDase was also expressed in vascular SMC and down-regulated in atherosclerotic lesions, being more significantly decreased in patients with unstable, than stable angina. These findings suggest that E-NTPDase expression by SMC is also reduced by inflammatory and/or oxidative stress. The local expression of E-NTPDase by gene transfer in the injured arterial walls of rats significantly suppresses platelet aggregation and occlusive thrombus formation. These lines of evidence suggest that reduced E-NTPDase activity in atherosclerotic lesions largely promotes thrombus formation on disrupted plaques.

2) C-Type Lectin-Like Receptor 2

Platelet activation is mediated by platelet-specific receptors including those for glycoprotein (GP) Ib, GPVI, GPIIb/IIIa, protease activated receptors (PAR) 1, PAR4, and P2Y. C-type lectin-like receptor 2 (CLEC-2) is a novel receptor for the platelet-activating, snake-venom protein, rhodocytin. CLEC-2 elicits powerful platelet activation signals in conjunction with Src, Syk kinases, and phospholipase C, like the collagen receptor GPVI/FcRγ-chain complex. Therefore, endogenous ligands for CLEC-2 in vessel walls contribute to thrombosis and hemostasis. Podoplanin has recently become recognized as an endogenous ligand for CLEC-2. Hatakeyama et al. showed that podoplanin was expressed in human advanced, but not early atherosclerotic lesions (diffuse intimal thickening), that primarily consist of SMC. Inoue et al. showed that SMC stimulate platelets through binding CLEC-2 and identified S100A13 as one of its ligands. S100A13 is a Ca2+-binding protein that belongs to the S100 protein family, and it is implicated in inflammation, angiogenesis and tumor development. S100A13 is expressed on the surface of SMC under oxidative stress, but not on that of normal SMC. Increased amounts of CLEC-2 ligands, podoplanin and S100A13 in advanced atherosclerotic plaques access platelet activation and promote thrombus formation.

Coagulation Factors on Thrombus Formation

The coagulation pathway also plays a critical role in thrombus formation. The binding of plasma factor VIIa (FVIIa) to tissue factor (TF) initiates this pathway, and TF/FVIIa complexes of the extrinsic pathway initiate blood coagulation by activating both FX and FXa. The FVIIa/FXa complexes of the intrinsic pathway provide an alternative route to the generation of FXa, which is part of the prothrombinase complex (FVa/FXa) that activates prothrombin to thrombin that subsequently plays a central role in the coagulation protease cascade. In addition, activated platelets enhance the coagulation cascade by providing a negatively charged phospholipid surface for the assembly of prothrombinase complexes and by binding FXI via the GPIb receptor.

TF triggers the extrinsic pathway, and it is widely distributed in non-uniform tissues of the brain, lungs, heart, kidneys and other organs. Adventitial fibroblasts in normal arteries, as well as macrophages and SMC in atherosclerotic lesions express TF, large amounts of which locate in the extracellular matrix of advanced lesions in humans. These pathological findings indicate that TF expression in atherosclerotic plaques plays a major procoagulant role in thrombus formation after plaque disruption. Mallat et al. reported that 97% of the total procoagulant activity extracted from atherosclerotic plaques was due to TF. In addition, TF circulates in a blood microparticle (MP)-associated form, and clinical studies have identified increased amounts of TF antigen circulating in the plasma of patients with cardiovascular disease (CAD). However, Hisada et al. reported that the activity of the MP-associated form of TF did not significantly increase in the cardiovascular disease patients; therefore, plaques...
whereas small thrombi that developed on the injured normal artery were rich in platelets (Fig. 2)\(^{35}\). The intravenous injection of a recombinant TF pathway inhibitor (TFPI) or TFPI gene transfection into injured vessel walls significantly reduced thrombus size, suggesting that thrombus formation on arterial lesion largely depends on the TF-dependent coagulation pathway\(^{34, 36, 37}\).

**Rabbit Model of Atherothrombosis**

We developed an animal model that expressed TF in vascular lesions to understand the role of TF in plaques on thrombus formation\(^{33-35}\). Plaques were created in rabbit arteries injured using a balloon catheter and, then, the rabbits were fed with either a conventional or a cholesterol diet to developing SMC- or macrophage-rich plaques, respectively. The expression and activities of TF increased in both types of plaques, with more being localized in the macrophage-rich types\(^{35}\); this mimics the situation in human atherosclerotic plaques.

Large thrombi produced on injured plaques in this model comprised a mixture of platelets and fibrin, whereas small thrombi that developed on the injured normal artery were rich in platelets (Fig. 2)\(^{35}\). The intravenous injection of a recombinant TF pathway inhibitor (TFPI) or TFPI gene transfection into injured vessel walls significantly reduced thrombus size, suggesting that thrombus formation on arterial lesion largely depends on the TF-dependent coagulation pathway\(^{34, 36, 37}\).

**Tissue Factor Expression in Plaques**

The expression of TF in vascular cells is induced by many factors, such as proinflammatory cytokines (interleukin-1, tumor necrosis factor-a), bacterial endotoxin and modified low density lipoprotein\(^{38}\).

1) C-Reactive Protein

C-reactive protein (CRP) is an inflammatory acute-
phase reactant that has emerged as a powerful predictor of CAD. This protein is present in all stages of atherosclerotic plaques from the early to advanced lesions, and more prevalent in thrombotic, than non-thrombotic plaques, implicating CRP in atherothrombogenesis. Because CRP functions in rabbits but not in mice as an acute-phase reactant during inflammation in the same way that it does in humans, Koike et al. established a line of transgenic (Tg) rabbits that overexpressed human CRP (hCRP). Matsuda et al. found that hCRP enhanced vascular wall thrombogenicity via increased TF expression in SMC and promoted thrombus formation after plaque disruption in this model.

2) Plaque Hypoxia

Hypoxia affects the biological functions of vascular cells via the regulation of metabolism, inflammation, angiogenesis and several other processes. Hypoxia signaling can modulate tissue remodeling or the severity of cardiovascular disorders. Hypoxia inducible factor-1α (HIF-1α) and HIF-2α belong to a group of transcription factors that mediate most of the cellular responses to hypoxia at the transcriptional level. Sluimer et al. demonstrated that hypoxia was present in the center of an advanced human carotid plaque by pimonidazole hydrochloride, a hypoxic marker, and also that the hypoxic area, HIF and macrophages were correlated with intra-plaque angiogenesis. Plaque hypoxia has been detected in animal models of atherosclerosis. Leppänen et al. revealed that even though the rabbit normal aorta was not hypoxic, the cores of plaques > 500 µm thick were hypoxic, and they were characterized by ATP depletion, low glucose, low glycogen and high lactate values. These findings suggest that limited oxygen diffusion capacity due to increased plaque thickness is a potent determinant of the onset of hypoxia within atherosclerotic lesions. Matsuurah et al. also detected hypoxic areas located predominantly within lipid-laden macrophage-rich plaque in a rabbit model of atherosclerosis. These hypoxic areas positively correlated with the number of HIF-1α and NF-κB p65-immunopositive nuclei and TF-immunopositivity. They also found hypoxic conditions increased TF and plasminogen activator inhibitor (PAI)-1 expression and pro-coagulant activity in atherosclerotic plaque tissues and cultured macrophages. These results suggest that hypoxia itself is an important determinant of TF expression. O’Rourke et al. reported that hypoxia can induce TF mRNA in HIF-1α-deficient HeLa cells, suggesting that hypoxia could also increase TF independently of HIF-1α.

Non-Hemostatic Functions for TF

Accumulating evidence shows that TF/FVIIa complexes not only initiate the coagulation pathway, but also affect various non-hemostatic biological agents by activating proteinase-activated receptors (PARs). Many cell types express these receptors, which play important roles in cardiovascular physiology and pathophysiology, and in the systems of other many organs. The TF/FVIIa complex, FXa and thrombin are potent PAR activators. Therefore, TF/FVIIa complex directly or indirectly activates PARs (Fig. 3), which mediate contraction, migration, proliferation, hypertrophy, and production of the extracellular matrix of SMC, thereby contributing to the development of vascular lesions and the pathophysiology of vascular diseases such as atherosclerosis. Furthermore, the cytoplasmic domain of TF serves as a regulator for angiogenesis and SMC migration/proliferation. Therefore, TF expressed in plaques contributes to not only thrombus formation after plaque disruption, but also contributes to the development of plaque.

Factors That Contribute to Thrombus Propagation

Thrombus formation on disrupted plaques is a fundamental process in the onset of acute cardiovascular events. However, it does not always lead to complete thrombotic occlusion with subsequent acute symptomatic events. Autopsy studies of patients who died of non-cardiac causes have found a 4% – 10% incidence of coronary plaque disruption with fresh non-occlusive thrombi. Clinical studies using invasive vascular imaging techniques have revealed a much higher incidence of asymptomatic coronary plaque disruption, and multiple plaque disruption is a frequent complication in patients with ACS. Disrupted plaques at various stages of healing are also occasionally found post-mortem in patients with or without ACS. Furthermore, several pathologic studies of aspirated coronary material have shown that plaque disruption and thrombus formation occur significantly earlier than symptom onset, coronary thrombi are days or weeks old in many patients, and the presence of an older thrombus is an independent predictor of mid or long-term mortality in patients with acute myocardial infarction (MI). This evidence indicates that coronary plaque disruption with thrombosis is rather prevalent and that many lesions might not be associated with acute symptomatic events. Therefore, other factors affecting thrombus propagation must contribute to the onset of acute coronary events.
increased thrombogenicity of vascular walls is crucial for thrombus formation and propagation (Fig. 4).

Blood flow velocity significantly affects the function of von Willebrand factor (VWF), a large multimeric glycoprotein that is synthesized and stored by endothelial cells and megakaryocytes. The VWF multimers released upon stimulation are rich in ultra-large (UL) forms that are hyperactive in binding platelet GP \( \beta \) and can induce platelet aggregation (80, 81). Released UL-VWF multimers are rapidly cleaved by the plasma protease, a disintegrin and metalloprotease with a thrombospondin type 1 motif 13 (ADAMTS-13), to smaller and less active forms under flow conditions (82). An extreme deficiency of ADAMTS-13 activity results in increased circulating levels of UL-VWF multimers that correlate with the onset of thrombotic thrombocytopenic purpura (TTP) (83). Shida et al. (84) reported that ADAMTS-13 cleaved VWF and down-regulated mural thrombus growth at the site of ongoing thrombus generation under high shear rate conditions. This evidence suggests that ADAMTS-13 prevents thrombus propagation and thrombotic occlusion by regulating the size of

1) Blood Flow Changes and VWF-ADAMTS13 Axis

Blood flow is a key modulator of thrombosis. Stenosis or irregular vessel geometries in advanced atherosclerotic arteries might induce disturbed blood flow (i.e., flow separation, recirculation, and reattachment of forward flow) that are thought to favor thrombus propagation (72, 73). In addition, plaque disruption and coronary intervention can induce distal embolisms and vasoconstriction, which reduce or disrupt coronary blood flow at sites of plaque disruption (74-76). Regions with low wall shear stress, particularly oscillatory or reversed shear stress that can occur at bifurcations or at sites distal to stenotic lesions, are likely associated with the recruitment of platelets and coagulation factors (73). Reduced blood flow promoted fibrin-rich mural thrombi on atherosclerotic lesions in our animal model (77). Disrupted blood flow induced by luminal stenosis can induce plaque disruption (erosion), and computational flow simulation suggests that increased wall shear stress, turbulence kinetic energy and blood pressure significantly contribute to the onset of plaque erosion (78). The combination of changes in blood flow and the

Fig. 3. Tissue factor-dependent coagulation pathway and PARs
Membrane- and microparticle (MP)-associated TF binding to factor \( \alpha \) triggers coagulation pathway, whereas soluble form of TF with factor \( \alpha \) does not. Downstream coagulation factors activate proteinase-activated receptors (PARs) that play other non-coagulative biological roles.
prekallikrein to generate active kallikrein, and activate FXI. Factor XI is also activated by thrombin and is essential for further thrombin generation during thrombus formation\(^{92}\). It also causes the inhibition of fibrinolysis that is dependent on thrombin activatable fibrinolysis inhibitor (TAFI)\(^{93}\). These lines of evidence indicate that FXI-mediated thrombin activation and inhibited fibrinolysis contribute to thrombus propagation.

On the other hand, FXI is generally considered to be less important in normal hemostasis, because patients with an FXI deficiency have a mild or absent bleeding tendency and a mild trauma-induced bleeding disorder\(^{94,95}\). However, recent findings indicate that FXI is activated during blood coagulation, and that even small amounts of FXI can induce thrombus growth by generating thrombin and by protecting thrombi.

VWF multimers under high shear rate conditions. Clinical studies have found decreased ADAMTS-13 activity or a higher ratio of VWF/ADAMTS-13 in patients with acute MI\(^{85-87}\). We reported that ADAMTS-13 closely localized with VWF in coronary thrombi from patients with ACS, and that reducing ADAMTS-13 activity enhanced thrombus formation\(^{88}\). ADAMTS-13 activity is decreased during aging, in systemic inflammation, and in focal vascular inflammation\(^{89-91}\).

2) Factor XI in the Intrinsic Coagulation Pathway

The intrinsic coagulation pathway is essential for thrombus stabilization and propagation. This pathway is activated when blood contacts negatively charged substances or artificial surfaces and induces the conversion of FXII into activated FXII, which then cleaves

---

Fig. 4. Computational flow simulation and microphotographs of erosive injury of rabbit stenotic femoral artery with SMC-rich plaque

Rabbit femoral arteries 3 weeks after balloon injury are constricted using a vascular occluder. (A) Representative computational reconstructed image and flow simulation in Reynolds-Averaged Navier-Stokes model. Red and blue mesh indicates high and low pressure, respectively, on wall. Flow velocity in this model increases at stenosis and decreases at post-stenotic portion, resulting in disrupted flow. (B, C) Representative microphotographs of erosive injury and thrombus formation. Neointimal endothelial cells and SMCs are broadly detached at post-stenotic portion 15 minute after vascular stenosis (B) (Ref. 79, with permission). Large mural thrombi are formed at the portion 60 minute after vascular stenosis (C).
from fibrinolysis via TAFI. Therefore, FXI apparently plays a critical role in thrombus stability and propagation. Clinical studies have associated high levels of FXI with the onset of venous thrombosis and ischemic stroke\(^96-98\), whereas patients with a congenital FXI deficiency appear to be protected from these diseases\(^99-101\). We showed that inhibiting FXI activity suppressed thrombus propagation without prolonging bleeding time in a rabbit model of arterial and venous thrombosis\(^102-104\). Other clinical and experimental animal studies have also shown that lowering plasma FXI activity reduces thrombus formation while minimally affecting bleeding time\(^105, 106\).

These findings together indicate that plasma FXI plays a pivotal role in thrombus propagation and that FXI is a potential therapeutic target for preventing thrombosis without the adverse effect of bleeding.

**Conclusion**

Atherosclerotic plaques are in a prothrombotic state. The downregulation of E-NTPDase as well as nitric oxide and prostaglandin I\(_2\) in plaque endothelial cells promotes platelet activation, and increased podoplanin and S100A13 expression also activates platelets via CLEC-2. Furthermore, high levels of TF are expressed in plaques under conditions of inflammation, oxidative stress and hypoxia that together largely promote thrombus formation at sites of plaque disruption. Intrinsic coagulation factors and changes in blood flow also play critical roles in thrombus propagation, leading to clinical manifestations (Fig. 5).

**Acknowledgments**

This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (20390102, 23390084, 16H05163), an Intramural Research Fund (25-4-3) for Cardiovascular Diseases from the National Cerebral and Cardiovascular Center, and for Clinical Research from Miyazaki University Hospital.
Conflict of Interest

None declared

References

1) Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657-671
2) Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 1262-1275
3) Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003; 41: 155-225
4) Komohara Y, Fujiwara Y, Ohnishi K, Shiraishi D, Takeya M. Contribution of macrophage polarization to metabolic diseases. J Atheroscler Thromb. 2016; 23: 10-17
5) Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013; 368: 2004-2013
6) White SJ, Newby AC, Johnson TW. Endothelial erosion of plaques as a substrate for coronary thrombosis. Thromb Haemost. 2016; 115: 509-519
7) Quillard T, Araújo HA, Franck G, Shvartz E, Sukhova G, Libby P. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J. 2015; 36: 1394-1404
8) Sato Y, Hatakeyama K, Yamashita A, Marutsuka K, Sumiyoshi A, Asada Y. Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans. Heart. 2005; 91: 526-530
9) Yamashita A, Sumi T, Goto S, Hoshiba Y, Nishihira K, Kawamoto R, Hatakeyama K, Date H, Imamura T, Ogawa H, Asada Y. Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. Am J Cardiol. 2006; 97: 26-28
10) Hoshiba Y, Hatakeyama K, Tanabe T, Asada Y, Goto S. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. J Thromb Haemost. 2006; 4: 114-120
11) Gachet C, Leon C, Hechler B. The platelet P2 receptors in arterial thrombosis. Blood Cells Mol Dis. 2006; 36: 223-227
12) Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost. 2005; 31: 217-233
13) Marcus AJ, Broekman MJ, Drosopoulos JH, Olson KE, Islam N, Pinsky DJ, Levi R. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost. 2005; 31: 234-246
14) Robson SC, Kaczmarek E, Siegel JB, Candinas D, Koziai K, Millan M, Hancock WW, Bach FH. Loss of ATP diphosphohydrolase activity with endothelial cell activation J Exp Med. 1997; 185: 153-163
15) Kanthi Y, Hyman MC, Liao H, Baek AE, Visovatti SH, Sutton NR, Goonewardena SN, Neral MK, Jo H, Pinsky DJ. Flow-dependent expression of ectonucleotide tri(di)phosphohydrolase-1 and suppression of atherosclerosis. J Clin Invest. 2015; 125: 3027-3036
16) Hatakeyama K, Hao H, Immamura T, Ishikawa T, Shibata Y, Fujimura Y, Eto T, Asada Y. Relation of CD39 to plaque instability and thrombus formation in directional atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol. 2005; 95: 632-625
17) Furukoji E, Matsumoto M, Yamashita A, Yagi H, Sakurai Y, Marutsuka K, Hatakeyama K, Morishita K, Fujimura Y, Tamura S, Asada Y. Adenovirus-mediated transfer of human placental ectonucleoside triphosphate diphosphohydrolase to vascular smooth muscle cells suppresses platelet aggregation in vitro and arterial thrombus formation in vivo. Circulation. 2005; 111: 808-815
18) Jamashi J, Ayabe K, Goto S, Nieswanndt B, Peter K, Siess W. Platelet receptors as therapeutic targets: Past, present and future. Thromb Haemost. 2017; 117: 1249-1257
19) Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. J Thromb Haemost. 2011; 9 Suppl 1: 44-55
20) Hatakeyama K, Kaneko MK, Kato Y, Ishikawa T, Nishihira K, Tsujimoto Y, Shibata Y, Ozaki Y, Asada Y. Podoplanin expression in advanced atherosclerotic lesions of human aortas. Thromb Res. 2012; 129: e70-76
21) Inoue O, Hokamura K, Shirai T, Osada M, Tsukiji N, Hatakeyama K, Umemura K, Asada Y, Suzuki-Inoue K, Ozaki Y. Vascular smooth muscle cells stimulate platelets and facilitate thrombus formation through platelet CLEC-2: Implications in atherothrombosis. PLoS One. 2015; 10: e0139357
22) Massi D, Landriscina M, Piscazzi A, Cosci E, Kirov A, Paglierani M, Di Serio C, Mournouras V, Fumagalli S, Biagioli M, Prudovsky I, Miracco C, Santucci M, Marchionni N, Tarantini F. S100A13 is a new angiogenic marker in human melanoma. Mod Pathol. 2010; 23: 804-813
23) Pierce A, Barron N, Linehan R, Ryan E, O’Driscoll L, Daly C, Clynes M. Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines. Eur J Cancer. 2008; 44: 151-159
24) Grant MA, Aird WC. Molecular evolution of the vertebrate blood coagulation system. Hemostasis and Thrombosis, 6th ed, Marder VJ, Arid WC, Bennett JS, Schulman S, White GC II, Lippincott Williams & Wilkins, 2013, pp11-25
25) Baglia FA, Badellino KO, Li CQ, Lopez JA, Walsh PN. Factor XI binding to the platelet glycoprotein IbIX-V complex promotes factor XI activation by thrombin. J Biol Chem 2002; 277: 1662-1668
26) Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989; 134: 1087-1097
27) Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989; 86: 2839-2843
28) Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis. 1997; 133: 213-219

29) Mallat Z, Hugel B, Ohan J, Lesche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 1999; 99: 348-353

30) Nomura S. Microparticle and atherothrombotic diseases. J Atheroscler Thromb. 2016; 23: 1-9

31) Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011; 108: 1284-1297

32) Hisada Y, Alexander W, Kasthuri R, Voorhees P, Mobarrez F, Taylor A, McNamara C, Wallen H, Witkowski M, Key NS, Rauch U, Mackman N. Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays. Thromb Res. 2016; 139: 90-97

33) Hatakeyama K, Asada Y, Marutsuka K, Kataoka H, Sato Y, Sumiyoshi A. Expression of tissue factor in the rabbit aorta after balloon injury. Atherosclerosis. 1998; 139: 265-271

34) Asada Y, Hara S, Tsuneyoshi A, Hatakeyama K, Kisanuki A, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb Haemost. 1998; 80: 506-511

35) Yamashita A, Matsuda S, Matsumoto T, Moriguchi-Goto S, Takahashi M, Sugita C, Sumi T, Imamura T, Shima M, Kitamura K, Asada Y. Thrombin generation by internal tissue factor contributes to thrombus formation on macrophage-rich neointima but not normal intima of hyperlipidemic rabbits. Atherosclerosis. 2009; 206: 418-426

36) Nishida T, Ueno H, Atsushi N, Kawano R, Asada Y, Nakahara Y, Kamikubo Y, Takeshita A, Yasui H. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit. Circ Res. 1999; 84: 1446-1452

37) Atsushi N, Nishida T, Marutsuka K, Asada Y, Kamikubo Y, Takeshita A, Ueno H. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation. 2001; 103: 570-575

38) Riedker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007; 49: 2129-2138

40) Emerging Risk Factors Collaboration, Kaptoe S, Di Angelantonio E, Lowe G, Pepsys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010; 375: 132-140

41) Kitagawa K, Hosomi N, Nagai Y, Kagimura T, Ohtsuki T, Oogasa H, Minematsu K, Uchiyama S, Nakamura M, Matsumoto M; J-STARS Investigators. Reduction in high-sensitivity C-reactive protein levels in patients with ischemic stroke by statin treatment: Hs-CRP Sub-Study in J-STARS. J Atheroscler Thromb. 2017; 24: 1039-1047

42) Sun H, Koike T, Ichikawa T, Hatakeyama K, Shimoi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005; 167: 1139-1148

43) Ishikawa T, Hatakeyama K, Imamura T, Date H, Shibata Y, Hikichi Y, Asada Y, Eto T. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol. 2003; 91: 287-292

44) Torzewski J. C-reactive protein and atherogenesis: new insights from established animal models. Am J Pathol. 2005; 167: 923-925

45) Koike T, Kitajima S, Yu Y, Nishijima K, Zhang J, Ozaki Y, Morimoto M, Watanabe T, Bhakdi S, Asada Y, Chen YE, Fan J. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation. 2009; 120: 2088-2094

46) Matsuda S, Yamashita A, Sato Y, Kitajima S, Koike T, Sugita C, Moriguchi-Goto S, Hatakeyama K, Takahashi M, Koshimoto C, Matsuura Y, Ikawira T, Chen YE, Fan J, Asada Y. Human C-reactive protein enhances thrombus formation after neointimal balloon injury in transgenic rabbits. J Thromb Haemost. 2011; 9: 201-208

47) Semenza GL. Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med. 2010; 2: 336-361

48) Abe H, Semb H, Takeda N. The Roles of Hypoxia Signaling in the Pathogenesis of Cardiovascular Diseases. J Atheroscler Thromb. 2017; 24: 884-894

49) Sliuiter JC, Gasc JM, van Wanroij JL, Kisters N, Grooteweg M, Sollewijn Gelpke MD, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, Bijnenes AP. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008; 51: 1258-1265

50) Matsuura Y, Yamashita A, Ikawira T, Sugita C, Okuyama N, Kitamura K, Asada Y. Vascular wall hypoxia promotes arterial thrombus formation via augmentation of vascular thrombogenicity. Thromb Haemost. 2015; 114: 158-172

51) Nie X, Randolph GJ, Elvington A, Bandara N, Zeleznyak A, Groper RJ, Woodard PK, Lapi SE. Imaging of hypoxia in mouse atherosclerotic plaques with 64 Cu-ATSM. Nucl Med Biol. 2016; 43: 534-542

52) Leppänen O, Björnheden T, Evaldsson M, Borén J, Wiklund O, Levin M. ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis. 2006; 188: 323-330

53) O'Rourke JE, Pugh CW, Bartlett SM, Ratcliffe PJ. Identification of hypoxically inducible mRNAs in HeLa cells.
using differential-display PCR. Role of hypoxia-inducible factor-1. Eur J Biochem. 1996; 241: 403-410

54) Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004; 24: 1015-1022

55) Isermann B. Homeostatic effects of coagulation protease-dependent signaling and protease activated receptors. J Thromb Haemost. 2017; 15: 1273-1284

56) Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Kami-kubo Y, Sumiyoshi A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIII complex. Thromb Haemost. 1997; 78: 1138-1141

57) Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumi-yoshi A, Asada Y. Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIII complex. Thromb Res. 2002; 107: 271-276

58) Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007; 27: 27-36

59) Alberelli MA, De Candia E. Functional role of protease activated receptors in vascular biology. Vascul Pharmacol. 2014; 62: 72-81

60) Belting M, Dorrell M, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller B, Friedlander M, Ruf W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004; 10: 502-509

61) Otto I, Michaelis C, Schuermann M, Steppich B, Seitz I, Dewerchin M, Zohlnhofer D, Wessely R, Rudelius M, Schoming A, Carmeliet P. Vascular remodeling in mice lacking the cytoplasmic domain of tissue factor. Circ Res. 2005; 97: 293-298

62) Davies MJ, Bland JM, Hangartner JR, Angelini A, Thomas AC. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989; 10: 203-208

63) Arbuslini E, Grasso M, Diegoli M, Mombini P, Aguzzi E, Fasani R, et al. Coronary thrombosis in non-cardiac death. Coron Artery Dis 1993; 4: 751-759

64) Sato Y, Hatakeyama K, Marutsuka K, Asada Y. Incidence of asymptomatic coronary thrombosis and plaque disruption: comparison of non-cardiac and cardiac deaths among autopsy cases. Thromb Res. 2009; 124: 19-23

65) Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF, Tabib A. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002; 106: 804-808

66) Kotani J, Mintz GS, Castagna MT, Pinnow E, Berzinger CO, Bui AB, Pichard AD, Satler LF, Suddath WO, Waksman R, Laird JR Jr, Kent KM, Weissman NJ. Intravascular ultrasound analysis of infarct-related and non-infarct-related arteries in patients who presented with an acute myocardial infarction. Circulation 2003; 107: 2889-2893

67) Shimamura K, Ino Y, Kudo T, Nishiguchi T, Tanimoto T, Ozaki Y, Satogami K, Orii M, Shiono Y, Komukai K, Yamano T, Matsuo Y, Kitabata H, Yamaguchi T, Hirata K, Tanaka A, Imanishi T, Akasaka T. Difference of ruptured plaque morphology between asymptomatic coronary artery disease and non-ST elevation acute coronary syndrome patients: an optical coherence tomography study. Atherosclerosis. 2014; 235: 532-537

68) Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, Virmani R. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103: 934-940

69) Rittersma SZ, van der Wal AC, Koch KT, Piek JJ, Henriques JP, Mulder KJ, Ploegmakers JP, Meesterman M, de Winter RJ. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention. Circulation. 2005; 111: 1160-1165

70) Kramer MC, van der Wal AC, Koch KT, Ploegmakers JP, van der Schaaf RJ, Henriques JP, Baan J Jr, Rittersma SZ, Vis MM, Piek JJ, Tijssen JG, de Winter RJ. Presence of older thrombus is an independent predictor of long-term mortality in patients with ST-elevation myocardial infarction treated with thrombus aspiration during primary percutaneous coronary intervention. Circulation. 2008; 118: 1810-1816

71) Nishihira K, Shibata Y, Yamashita A, Kuriyama N, Asada Y. Relationship between thrombus age in aspired coronary material and mid-term major adverse cardiac and cerebrovascular events in patients with acute myocardial infarction. Atherosclerosis. 2018; 268: 138-144

72) Chatzizisis YS, Coskun UA, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling. J Am Coll Cardiol. 2002; 49: 2379-2393

73) Hathcock JJ. Flow effects on coagulation and thrombosis. Arterioscler Thromb Vasc Biol. 2006; 26: 1729-1737

74) Marzilli M, Sambuceti G, Fedele S, L’Abbate A. Coronary microcirculatory vasoconstriction during ischemia in patients with unstable angina. Am J Coll Cardiol 2000; 35: 327-334

75) Heusch G, Kleinbongard P, Böse D, Levkau B, Haude M, Schulz R, Erbel R. Coronary microembolization: from bedside to bench and back to bedside. Circulation. 2009; 120: 1822-1836

76) Teramoto R, Sakata K, Miwa K, Matsubara T, Yasuda T, Inoue M, Okada H, Kanaya H, Kawashiri MA, Yamagishi M, Hayashi K. Impact of Distal protection with filter-type device on long-term outcome after percutaneous coronary intervention for acute myocardial infarction: clinical results with Filtrap®. J Atheroscler Thromb. 2016; 23: 1313-1323

77) Yamashita A, Furukoji E, Marutsuka K, Hatakeyama K, Yamamoto H, Tamura S, Ikeda Y, Sumiyoshi A, Asada Y. Increased vascular wall thrombogenicity combined with reduced blood flow promotes occlusive thrombus formation in rabbit femoral artery. Arterioscler Thromb Vasc Biol. 2004; 24: 2420-2424

78) Sameshima N, Yamashita A, Sato S, Matsuda S, Matsuura Y, Asada Y. The value of wall shear stress, turbulence kinetic energy and blood pressure gradient are associated with atherosclerotic plaque erosion in rabbits. J Atheroscler Thromb. 2014; 21: 831-838

79) Sumi T, Yamashita A, Matsuda S, Goto S, Nishihira K,
Furukoji E, Sugimura H, Kawahara H, Imamura T, Kitamura K, Tamura S, Asada Y. Disturbed blood flow induces erosive injury to smooth muscle cell-rich neointima and promotes thrombus formation in rabbit femoral arteries. J Thromb Haemost. 2010; 8: 1394-1402

80) Franchini M, Lippi G. Von Willebrand factor and thrombosis. Ann Hematol. 2006; 85: 415-423

81) Shiozaki S, Takagi S, Goto S. Prediction of molecular interaction between platelet glycoprotein Ibα and von Willebrand factor using molecular dynamics simulations. J Atheroscler Thromb. 2016; 23: 455-464

82) Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns metalloprotease that cleaves von Willebrand factor. Blood. 1995; 86: 3035-3042

83) Franchini M, Lippi G. Von Willebrand factor and thrombosis. Ann Hematol. 2006; 85: 415-423

84) Shiozaki S, Takagi S, Goto S. Prediction of molecular interaction between platelet glycoprotein Ibα and von Willebrand factor using molecular dynamics simulations. J Atheroscler Thromb. 2016; 23: 455-464

85) Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost. 2006; 4: 2490-2493

86) Horii M, Uemura S, Uemura M, Matsumoto M, Ishizashi H, Imagawa K, Iwama H, Takeda Y, Kawata H, Nakajima T, Fujimura Y, Saito Y. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. Heart Vessels. 2008; 30: 301-307

87) Maino A, Siegertink B, Lotta LA, Crawley JT, le Cessie S, J Thromb Haemost. 2010; 8: 1394-1402

88) Reiter RA, Varadi K, Turecek PL, Jilma B, Keob P. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost. 2005; 93: 554-558

89) Gandhi C, Khan MM, Lentz SR, Chauhan AK. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood. 2012; 119: 2385-2391

90) von dem Borne PAK, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest. 1997: 99: 2323-2327

91) Bolton-Maggs PH. Factor XI deficiency and its management. Haemophilia. 2000; 6: 100-109

92) Schmaier AH. Physiologic activities of the contact activation system. Thromb Res. 2014; 133 Suppl 1: S41-44

93) Meijers JC, Tzeng I, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000; 342: 696-701

94) Berliner JL, Rybicki AC, Kaplan RC, Monrad ES, Freeman R, Billett HH. Elevated levels of factor XI are associated with cardiovascular disease in women. Thromb Res. 2002; 107: 55-60

95) Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol. 2006; 126: 411-415